Bioequivalence Between 180 mg and 60 mg ALXN2050 Tablets and Food Effect on ALXN2050 Pharmacokinetics

This is a single-center, open-label, randomized, 3-period crossover study. Screening of participants will occur within 28 days prior to the first dose of study intervention. The study will comprise of 3 Treatment Periods: Treatment period 1, Treatment period 2, Treatment period 3. There will be a washout period of at least 4 days between the ALXN2050 dose in each treatment period. Participants will be enrolled and will be randomized 1:1:1:1:1:1 to receive one of 6 treatment sequences (ABC, ACB, BAC, BCA, CAB, CBA). On the morning of Day 1 of each of the 3 periods, participants will receive one of the following treatments as per the randomization scheme. * Treatment A: Dose B of ALXN2050 tablet under fasted conditions * Treatment B: A single Dose A dose of ALXN2050 tablet under fasted conditions * Treatment C: A single Dose A dose of ALXN2050 tablet with a high-fat meal Duration of study conduct (screening to follow-up): approximately 47 days.